Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene.

Nokes BT, Cunliffe HE, Lafleur B, Mount DW, Livingston RB, Futscher BW, Lang JE.

J Cancer. 2013;4(2):104-16. doi: 10.7150/jca.5002. Epub 2013 Jan 10.

2.

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.

Breast Cancer Res Treat. 2006 Feb;95(3):219-28. Epub 2005 Oct 22.

PMID:
16244790
4.

Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling.

Ohshiro K, Schwartz AM, Levine PH, Kumar R.

PLoS One. 2012;7(1):e30725. doi: 10.1371/journal.pone.0030725. Epub 2012 Jan 25.

5.

Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines.

Hillyer RL, Sirinvasin P, Joglekar M, Sikes RA, van Golen KL, Nohe A.

Clin Exp Metastasis. 2012 Dec;29(8):971-9. doi: 10.1007/s10585-012-9486-0. Epub 2012 May 20.

PMID:
22610818
6.

Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.

Victor BC, Anbalagan A, Mohamed MM, Sloane BF, Cavallo-Medved D.

Breast Cancer Res. 2011;13(6):R115. doi: 10.1186/bcr3058. Epub 2011 Nov 17.

7.

The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.

Salem I, Alsalahi M, Chervoneva I, Aburto LD, Addya S, Ott GR, Ruggeri BA, Cristofanilli M, Fernandez SV.

Breast Cancer Res. 2016 Mar 24;18(1):37. doi: 10.1186/s13058-016-0694-4.

8.

Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.

Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cristofanilli M.

Cancer. 2010 Jun 1;116(11 Suppl):2806-14. doi: 10.1002/cncr.25167.

9.

Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.

Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M.

J Exp Ther Oncol. 2008;7(4):299-312.

PMID:
19227010
10.

Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes.

Menon R, Im H, Zhang EY, Wu SL, Chen R, Snyder M, Hancock WS, Omenn GS.

J Proteome Res. 2014 Jan 3;13(1):212-27. doi: 10.1021/pr400773v. Epub 2013 Nov 7.

11.

Human Mammary Tumor Virus (HMTV) sequences in human milk.

Nartey T, Moran H, Marin T, Arcaro KF, Anderton DL, Etkind P, Holland JF, Melana SM, Pogo BG.

Infect Agent Cancer. 2014 Jun 17;9:20. doi: 10.1186/1750-9378-9-20. eCollection 2014.

12.

Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer.

Madsen BE, Ramos EM, Boulard M, Duda K, Overgaard J, Nordsmark M, Wiuf C, Hansen LL.

PLoS One. 2008 Jun 25;3(6):e2492. doi: 10.1371/journal.pone.0002492.

13.

Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells.

Mineva ND, Paulson KE, Naber SP, Yee AS, Sonenshein GE.

PLoS One. 2013 Sep 11;8(9):e73464. doi: 10.1371/journal.pone.0073464. eCollection 2013.

14.

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.

Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR.

Breast Cancer Res Treat. 2013 Jan;137(2):359-71. doi: 10.1007/s10549-012-2352-6. Epub 2012 Dec 7.

PMID:
23225169
15.

Detection of human mammary tumor virus proteins in human breast cancer cells.

Melana SM, Nepomnaschy I, Hasa J, Djougarian A, Djougarian A, Holland JF, Pogo BG.

J Virol Methods. 2010 Jan;163(1):157-61. doi: 10.1016/j.jviromet.2009.09.015. Epub 2009 Sep 23.

PMID:
19781575
16.

MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer.

Wolfe AR, Bambhroliya A, Reddy JP, Debeb BG, Huo L, Larson R, Li L, Ueno NT, Woodward WA.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):791-9. doi: 10.1016/j.ijrobp.2016.01.025. Epub 2016 Jan 22.

PMID:
27055396
17.

Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56.

18.

RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.

van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD.

Neoplasia. 2000 Sep-Oct;2(5):418-25.

19.

Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models.

Suarez-Arroyo IJ, Rosario-Acevedo R, Aguilar-Perez A, Clemente PL, Cubano LA, Serrano J, Schneider RJ, Martínez-Montemayor MM.

PLoS One. 2013;8(2):e57431. doi: 10.1371/journal.pone.0057431. Epub 2013 Feb 28.

20.

In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line.

Hoffmeyer MR, Wall KM, Dharmawardhane SF.

Cancer Cell Int. 2005 Apr 27;5(1):11.

Items per page

Supplemental Content

Write to the Help Desk